Scleral device manages OSD

Article

The Prosthetic Replacement of the Ocular Surface Ecosystem (PROSE) device is a useful method of managing ocular surface disease (OSD) and optical imperfections, reveals a new study.

The Prosthetic Replacement of the Ocular Surface Ecosystem (PROSE) device is a useful method of managing ocular surface disease (OSD) and optical imperfections, reveals a new study.

A team managed by Dr Ryan Dimit, Alkek Eye Center, Baylor College of Medicine, Houston, Texas, USA, retrospectively reivewed the clinical outcomes of 51 charts of patients fitted unilaterally or bilaterally with the scleral device. The outcome measures included patient demographics, ocular diagnoses, associated systemic conditions, best corrected visual acuity (BCVA) before and after fitting, Visual Function Questionnaire scores (VFQ-25), and ocular surface disease index (OSDI) scores.

The most common reasons for wearing the PROSE device included relieving the symptoms of severe to moderate dry eye syndrome (DES), management of refractive problems and management of various anomalies (the "Other" group).

BCVA improved in wearers for those in with DES or refractive problems by 17 and 10 letters, respectively. However, BCVA did not improve for patients in the "Other" group.

There were no serious complications and the PROSE device is regarded as a useful management option for ophthalmic conditions such as moderate to severe DES and irregular corneal astigmatism.

The paper can be viewed in the Journal of the British Contact Lens Association.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.